NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nosopharm

Nosopharm

Private
LyonHealthcare & Life Scienceshttps://www.nosopharm.com/

Last Round

Debt

Feb 12, 2018

Total Funding Raised

$1.2M

Company Overview

Nosopharm is a biotechnology company that specializes in the research and development of new anti-infective drugs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

novel antibioticsantimicrobial resistanceAMROdilorhabdinssuperbug treatmentmultidrug-resistant pathogensNOSO-502anti-infective drug discoveryfirst-in-class antibioticGram-negative pathogensCarbapenem-Resistant EnterobacteralesCREdrug discovery platformhospital-acquired infectionsnatural product discoverynovel mechanism of action

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nosopharm Comparables

Compare Nosopharm with similar companies based on industry and business-model similarity.

Nosopharm comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VenatoRx Pharmaceuticals
76%
Bioversys
76%
Spero Therapeutics, Inc.
75%

Nosopharm Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtFeb 12, 2018
VC RoundMar 28, 2017

Nosopharm Investors

Notable investors and investment history

Nosopharm investors
InvestorRounds
Alto InvestVC Round
KreaxiVC Round
Région OccitanieGrant
Auriga PartnersVC Round
BpifranceGrant, Debt
Direction générale de l'armement (DGA)Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 12, 2018

    $1.2M round led by Bpifrance

  • Mar 28, 2017

    Raised $2.6M from Alto Invest, Auriga Partners, and Kreaxi.

Nosopharm Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nosopharm Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nosopharm's valuation, stock price, and market status.

Firmographic Details

HeadquartersLyon
Employee Range1
Year Founded2009
Last FundingFeb 12, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.